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Abstract 
 
Background: F-box and WD40 repeat domain-containing 7 (FBXW7) is an 
E3 ubiquitin ligase involved in the ubiquitination and degradation of multiple 
oncogenic substrates. The tumour suppressor function is frequently lost in 
multiple cancers through genetic deletion and mutations in a broad-range of 
tumours. Loss of FBXW7 functionality results in the stabilisation of multiple 
major oncoproteins, culminating in increased cellular proliferation and pro-
survival pathways, cell cycle deregulation, chromosomal instability and altered 
metabolism. Currently there is no therapy to specifically target FBXW7 
deficient tumours.  
Methods: We performed a siRNA kinome screen to identify synthetically 
lethal hits to FBXW7-deficiency.  
Results: We identified and validated Cyclin G associated kinase (GAK) as a 
potential new therapeutic target. Combined loss of FBXW7 and GAK caused 
cell cycle defects, formation of multipolar mitoses and the induction of 
apoptosis. The synthetic lethal mechanism appears to be independent of 
clathrin mediated receptor endocytosis function of GAK. 
Interpretation: These data suggest a putative therapeutic strategy for a large 
number of different types of human cancers with FBXW7 loss; many of which 
have a paucity of molecular abnormalities and treatment options.   
 
Keywords: 
FBXW7/FBX7, Cyclin G associated Kinase, Kinome, RNAi, Screen 
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Introduction:  
 
F-box and-WD-repeat-domain-containing 7 (FBXW7) is one of the most 
frequently perturbed proteins in the ubiquitin-proteosome system in cancer. 
FBXW7 is an E3 ubiquitin ligase that degrades an extensive list of oncogenes 
(Inuzuka et al, 2011; Welcker & Clurman, 2008; Wertz et al, 2011). It acts as a 
bridging molecule by binding substrates, through its WD40 domain, and 
scaffold proteins through its F-box domain. This produces the SCFFBXW7 
complex that interacts with the ubiquitin-conjugating complex facilitating the 
transfer of ubiquitin onto the substrate signalling it’s degradation by the 26S 
proteasome.   
 
The SCFFBXW7 complex is responsible for the degradation of multiple 
oncogenic substrates including: cyclin E, c-MYC, c-JUN, NOTCH and MCL-1, 
as well as a plethora of other proteins (Davis et al, 2014). FBXW7 controls the 
cellular levels of multiple proteins involved in cell cycle regulation, cell 
proliferation, differentiation, signal transduction, lipid metabolism and anti-
apoptosis. Loss of FBXW7 function results in reduced substrate degradation 
and their overexpression, culminating in cell proliferation, cell cycle de-
regulation, chromosomal instability and activation of pro-survival pathways, as 
well as being associated with poor clinical outcomes and drug resistance 
(Davis et al, 2014; Welcker & Clurman, 2008; Wertz et al, 2011).  
 
The FBXW7 gene locus 4q32 is deleted in a third of cancers (Knuutila et al, 
1999) and copy loss occurs in 15% (Kan et al, 2010).  Multiple studies have 
detected FBXW7 somatic mutations in a wide range of tumours, including 
~40% of cholangiocarcinomas and T-cell acute lymphoblastic leukaemias, as 
well as in 4-10% of carcinomas of the endometrium, colon, breast and 
stomach (Akhoondi et al, 2007; Spruck et al, 2002). Targeting tumour cells 
with loss of the FBXW7, presents an important treatment strategy given its 
widespread involvement in carcinogenesis. Due to the inherent complexities 
of attempting to restore protein function, synthetic lethality provides a feasible 
strategy to identify vital proteins that cells have become dependent on, in the 
absence of the FBXW7 tumour suppressor, that can be inhibited to cause 
selective cancer cell death. This approach has been clinically validated 
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through the identification of PARP inhibitors for BRCA-deficient tumours 
(Ashworth, 2008; Farmer et al, 2005).  
 
Herein, we describe a high-throughput RNAi kinome screen using HCT116 
FBXW7 deficient cells, which contain the targeted deletion of the f-box 
domain, and their wild-type comparators (Jallepalli et al, 2001; Rajagopalan et 
al, 2004). We identify Cyclin G associated kinase (GAK) as a potential 
synthetic lethal partner with FBXW7 deficiency. The identification of the 
druggable target GAK capable of selective toxicity in FBXW7 deficient 
cancers has broad therapeutic applications across numerous tumour types. 
 
Material and Methods:  
Cell lines and compounds 
Cell lines obtained from ATCC were maintained according to supplier’s 
instructions. Authenticated isogenic FBXW7 HCT116 human colon cancer 
cells were a gift from Professor Vogelstein’s. Pitstop 2 (Abcam), Annexin V 
(BD Biosciences), Propidiuim iodide (Sigma), DAPI (Invitrogen). 
 
siRNA 
All siRNAs were used at 50 nmol final concentration (Dharmacon). Primary 
screen used the siGENOME smart pool human protein kinase library arrayed 
into 96-well plates. All deconvolution and subsequent RNA interference 
(RNAi) were undertaken using the Dharmacon catalogue. The individual GAK 
siRNA numbered 1-4 refer to siGENOME (SIG) and 5-8 On Target Plus 
(OTP).  Control siRNA included On Target Plus non-targeting (NT) and death 
(siTOX) control.  
 
Antibodies: α-tubulin (Sigma), aurora A (Cell Signaling), cleaved PARP (Cell 
Signaling), clathrin heavy chain (Abcam), FITC-conjugated mouse (Sigma) 
secondary antibody, GAPDH (VWR International), GAK mouse monoclonal 
(R&D systems), HRP-conjugated secondary antibodies (Sigma) and MPM-2 
(Millipore).  
 
RNAi for kinome screen and deconvolution  
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Cells at low passage, were split the day prior to reverse transfection. 
Conditions were optimised for each cell line so the NT controls were ~90% 
confluent by inspection under the microscope and the siTOX was <10% 
relative to the NT controls on day of measurement. Screen conditions: siRNA 
was mixed with transfection mixture of 0.19% Dharmafect 2 (Dharmacon) in 
OptiMEM (Invitrogen), aliquoted into 96-well plates in duplicate for two 
comparator cell lines. After 25 min incubation at room temperature, 3000 
FBXW7+/+ and -/- HCT116 cells in antibiotic free medium, were added 
respectively, and supplemented with double the volume of medium with 
antibiotics at 7 hours. On Day 5, medium was removed and 100 μl of CellTiter 
Glo (Promega) added, incubated at room temperature before quantifying 
luminescence using a Victor X5 Plate Reader (Perkin Elmer). Conditions were 
scaled up for 6 well plates using 50 nmol of siRNA, 0.25% Dharmafect 2 for 
400,000 HCT116 cells.  
 
Immunoblot analysis 
Whole cells extracts were prepared in Triton lysis buffer (120 mmol NaCl, 50 
mmol Tris pH 7.4, 1% Trition, 50 mmol NaF, 1 mmol EDTA, protease 
inhibitors). Protein concentration of supernatent quantified using the Bio-Rad 
protein assay. Equal amounts of protein (30 μg) were loaded onto precast 4-
12% Bis-Tris gels (Invitrogen) with a rainbow molecular weight marker (GE 
Healthcare, UK) as a size reference and separated by SDS-polyacrylamide 
gel electrophoresis. Proteins were transferred to nitrocellulose membranes 
(Sigma), blocked and probed with primary antibody diluted 1 in 1,000 in TBS-
Tween with 4% skimmed milk overnight at 40C. Secondary antibiodies were 
dilute 1 in 5,000 in TBS-T with 4% skimmed milk and incubated for 1 hour at 
room temperature. Protein bands were visualised using ECL chemi-
luminescence reagents followed by exposure on Kodak BioMAX film. 
 
Validation of RNAi gene silencing and viability assays.  
Validation of RNAi gene silencing was determined by immunoblot analysis 
and viability assays using individual oligonucleotides using 6 and 96 well plate 
siRNA conditions, respectively. Long-term cell survival assay: following 
forward siRNA transfection, 1000 cells were seeded in 6-well plates, complete 
media was replaced the next day and thrice weekly until day 14 when 
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surviving cells were washed with PBS, fixed with 10% trichloro-acetic acid 
(TCA) for 2 hours, washed with water and stained with Sulforhodamine B 
(SRB) for a minimum of 30 min. Wells were washed with 1% acetic acid and 
dried overnight before taking images. SRB was eluted using 1ml of 10 mmol 
Tris pH 10.5 per well, plates shaken for 5 min, before transferring 100 μl of 
dye to a 96-well plate and absorbance read at 490 nm by the Victor X5 Plate 
Reader (Perkin Elmer). 
 
Cell cycle profiling by flow cytometry 
All cells were harvested from 10-cm dishes using PBS then trypsin, 
centrifuged at 1000 rpm for 5 min, supernatant removed and the cell pellet re-
suspended in 150 μl of PBS to form a single-cell suspension. Cells were fixed 
using ethanol (–20 0C), to a final concentration of 75%, whilst gently vortexing; 
stored at –20 0C for 16 hours minimum prior to analysis. Thereafter, cells were 
washed with PBS, centrifuged at 1000 rpm for 5 min, and the supernatant 
removed. Cell pellets were re-suspended in MPM-2 antibody solution and 
incubated at 4 0C for one hour, washed with PBS, centrifuged as before, and 
re-suspended in FITC-conjugated secondary antibody (1:1000 in PBS) and 
incubated in the dark at 4 0C for 1 hour. Cells were washed in PBS, 
centrifuged and re-suspended in 500 μl propidium iodide (PI) solution: 40 
μg/ml PI, 50 μg/ml RNase A in PBS (Sigma). After 30 min incubation at room 
temperature, cells were analysed using the FACS analyser (BD Biosciences).  
 
Annexin V FITC assay  
Reverse transfection using NT control and GAK siGENOME SMARTpool 
siRNA was undertaken in 6-well plates using FBXW7+/+ and -/- HCT116 cells. 
Collected cells were ethanol fixed as per cell cycle protocol. Cell pellets were 
re-suspended in 500 μl medium containing 0.2% PI, 0.5% Annexin V and 
0.25% calcium chloride. After 15-minute incubation in the dark at room 
temperature, cells were transferred for FACS analysis (BD Biosciences).  
 
Immunofluorescence microscopy  
Cells were seeded onto 19-mm poly-L-lysine coated coverslips, cultured for 
24 hours, before being washed with PBS, and fixed in either 4% formaldehyde 
in PEM buffer for 10 min at room temperature or 100% methanol for 10 min at 
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–20 0C. Coverslips were washed in PBS containing 0.1% Triton X-100 (PBS-
T) and incubated with glycine blocking solution for 5 min at room temperature. 
Primary antibodies, diluted in blocking solution, were placed onto each 
coverslip and incubated at room temperature for 1 hour. Followed by washing 
in PBS-T and incubation with secondary antibodies for 30 min in the dark, 
repeat PBS-T wash and incubation in DAPI for 3 min, both at room 
temperature. Following final PBS-T wash, cells were mounted onto a glass 
slide, edges sealed and viewed using a fluorescence microscope (Zeiss LSM 
710). Where needed z-stacks were performed comprising of 10-30 images at 
0.1-0.5 μm intervals were captured, deconvoluted image stacks were 
projected on a single plane using Velocity software.  
 
Live-cell Timelapse imaging  
Generation of stable Histone H2b-mCherry HCT116 cells: 6 x 105 HCT116 
cells were seeded in a 6-well plate day prior to forward transfection. Medium 
aspirated, replaced with 500 μl optiMEM and transfection mixture added (2 μg 
of mcherry plasmid with 5 μl of L2000 transfection reagent in 500 μl of 
optiMEM), incubated at room temperature for 30 min. At 5 hours, medium was 
replaced with full medium containing antibiotics. Cells were expanded then 
harvested and the mCherry positive cells were selected using flow cytometric 
sorting, repeated twice to ensure a high percentage of expressing cells were 
isolated. For time-lapse imaging, cells were cultured in 96-well Ibidi plates. 
Images taken with a Nikon Eclipse TE2000-5 microscope, during which cells 
were maintained at 37 0C in a humidified stream of 5% CO2. Images were 
taken every 3 min for 24 hours with a 40X objective. FITC fluorescence was 
used for Histone H2b-mCherry cells, with anaphase onset judged as the first 
frame in which the sister-chromatids moved to the opposite spindle poles. 
Timelapse images were analysed using Image J software counting the 
number of frames from nuclear envelope break down to anaphase onset and 
data analysed by GraphPad prism. 
 
Cell viability assays for Pitstop 2 treatment 
Two thousand cells were seeded in 100 μl of medium in 96-well plates, 
incubated overnight at 37 0C. Two-fold serial dilutions of Pitstop 2 (Abcam) in 
medium were prepared with a DMSO control. An aliquot (50 μl) of drug or 
 8
DMSO preparation was added to the cells and incubated at 37 0C for four 
days when cell viability was quantified using the CellTiter-Glo assay, as 
described. Survival fractions were calculated by dividing the raw 
luminescence values for the drug treated well by the DMSO controls. Data 
were analysed using GraphPad Prism and survival curves determined. 
 
Statistical analysis 
siRNA high-throughput screen statistical analysis 
Raw luminescence readings for each well were log transformed and 
normalised to the NT controls on that plate. The effect of the SMARTpool 
targeting each gene on cell viability was expressed as a ∆Z-score. First the Z-
score was calculated, estimating the standard deviation of the normal 
distribution of the screen from the median absolute deviation of all 720 
SMARTpools, adjusted by a factor of 1.4826 (Abdi, 2007). The ∆Z-score was 
calculated by subtracting the Z-score for the FBXW7 wild-type from the 
deficient HCT116 cells. The mean ∆Z-score for the two runs was calculated 
for each SMARTpool. The Z’ factors were obtained using the NT and siTOX 
control wells, as a marker of the discriminatory power of the screen. 
 
Results:  
 
RNAi kinome screen identifies GAK as a putative synthetic lethal partner 
with FBXW7. 
 
In this study, we used a FBXW7 deficient HCT116 cell line, in order to identify 
potential genes that cause selective killing in FBXW7 deficient cells compared 
to the wild-type cells (Jallepalli et al, 2001; Rajagopalan et al, 2004). The 
FBXW7-/- cells contain bi-allelic deletion of the FBXW7 f-box domain resulting 
in a non-functional protein (if expressed) unable to bind or degrade its 
substrates. High throughput screening was undertaken by reverse 
transfection of 720 SMARTpool siRNAs targeting the human protein kinase 
library (Dharmacon) in 96-well format (Figure 1A), alongside non-targeting 
(NT) and a positive death (siTOX) controls, with the screen readout being cell 
viability on day 5 (Drosopoulos et al, 2014). The screen, conducted in 
duplicate, was highly reproducible (r2=0.89 and 0.85) and robust (mean Z’ 
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factors of 0.74 and 0.73) for FBXW7 wild-type and FBXW7-/- HCT116 cells, 
respectively (Supplementary Figure 1). The ranked mean ∆Z-scores of the 
two runs are shown in Figure 1B, a statistically significant threshold of ∆Z-
score < -2 was used to select hits for further validation. A secondary RNAi 
screen was undertaken to validate hits through the concept of redundancy 
and to exclude of target effects of the siRNAs used for the screen; genes 
would only be considered hits when at least two out of the four 
oligonucleotides causes selective cell death in FBXW7-/- cells, compared to 
the wild-type cells. The top 22 primary screen hit SMARTpools were 
deconvoluted into their 4 individual siRNAs and tested in triplicate under the 
primary screen conditions, with 7 potential hits validating (Supplementary 
table 1). The candidate gene, GAK, was validated as the lead hit, with all 8 
individual siRNAs (deconvoluted from two SMARTpools) producing a 
statistically significant increase in cell death in the FBXW7-/- compared to 
parental HCT116 cells (Figure 1C: mean 44.88% + 3.15 SEM versus 77.50% 
+ 3.52, respectively). Furthermore, cell death correlated with GAK gene 
silencing, with robust GAK protein knockdown with all 8 siRNAs (Figure 1D). 
GAK, or Auxilin 2, is a ubiquitously expressed cytosolic kinase involved in 
mitosis and receptor-mediated endocytosis (Kimura et al, 1997). The role of 
GAK in mitosis has been presented mainly in mitotic spindle assembly and 
chromosomal alignment (Shimizu et al, 2009; Tanenbaum et al, 2010). GAK 
functions in receptor-mediated endocytosis, through the formation of clathrin-
coated vesicles, involving the epidermal and insulin growth factor receptors 
(Susa et al, 2010; Zhang et al, 2004). 
 
To further test whether GAK RNAi caused a reduction in proliferation of 
FBXW7 deficient cells; GAK RNAi was used in 22 cell lines (9 FBXW7 
deficient and 13 proficient wild-type cell lines): 4 breast, 10 gynaecological 
and 8 colorectal (Supplementary Table 2). Given the small number of FBXW7 
mutant cell lines known and available, it was not possible to select cells of 
similar histological or biological subtypes. Rigorous optimisation was 
undertaken to identify the optimal conditions to ensure the least toxicity and 
most efficient transfections for each cell line (Figure 2,3). 
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The breast FBXW7 deficient (HCC1143, SUM149PT) and proficient (T47D, 
MCF7) cells demonstrated a clear relationship between FBXW7 loss of 
function and sensitivity to GAK knockdown, using two separate GAK 
SMARTpools, SIGENOME and OTP (Figure 2A). Combined analysis of the 
two FBXW7 deficient cell lines showed a significantly reduced median cell 
viability of 45.3% and 45.1%, compared to 63.8% and 98.6% for the two wild-
type comparators, for the respective SMARTpools (Figure 2B). This accorded 
with robust GAK protein knockdown (Figure 2C). To identify statistical 
significance the combined analysis of all the aforementioned breast cancer 
cell lines using both SMARTpools was undertaken. Each data point 
represents cell survival of the FBXW7 deficient HCC1143 and SUM149PT 
cells compared to the proficient T47D and MCF7 cells with the SIGENOME 
and OTP SMARTpools from triplicate experiments. This confirmed a highly 
statistically significant difference for the FBXW7 deficient cells with median 
survival of 43.8% versus 94.2%, p<0.0001 by paired T-test (Figure 2D).  
 
FBXW7 deficient gynaecological cell lines were not more sensitive to GAK 
RNAi compared to the FBXW7 wild-type cells (Figure 3A,B). Median cell 
survival of 46% versus 53% in FBXW7 deficient and proficient cells 
prospectively (Figure 3B) despite adequate protein knockdown (Figure 3C). 
Furthermore, the entire colon cancer cell panel was relatively insensitive to 
GAK inhibition (Figure 3D) despite good protein knockdown (Figure 3E). The 
cells showed similar low sensitivity to GAK RNAi whether they were FBXW7 
proficient or deficient, with median cell viabilities of 84% and 81%, 
respectively (Figure 3F). Hence, GAK depletion is not synthetically lethal to 
FBXW7 loss in colorectal or gynaecological cells lines. The small number of 
FBXW7 mutant cell lines available hindered investigation in a larger cell line 
panel.  
 
Dual GAK-FBXW7 inhibition induces apoptosis after 48 hours. 
 
To analyse the mode of death in the FBXW7-/- HCT116 cells, a long-term cell 
proliferation assay was performed for 14 days using two SMARTpools 
targeting GAK (Figure 4A,B). This confirmed that GAK RNAi was significantly 
more toxic to FBXW7-/- compared to the wild-type cells (Fig 4A), reducing cell 
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viability to ~10% with the siGENOME and 16% with the OTP pools, compared 
to 87% and 97% viability for FBXW7+/+ cells, respectively (Fig 4B). This is 
likely to indicate incremental FBXW7-/- killing over a prolonged time period, 
since the percentage cell death is higher at 14, compared to 5 days despite 
the fact the RNAi-mediated gene silencing would have ended.  
 
PARP cleavage was used to determine if the cells were undergoing 
apoptosis, at 72 and 96 hours following GAK RNAi (Figure 4C). In association 
with robust GAK protein knockdown following RNAi, there was a clear 
increase in cleaved PARP levels at both 72 and 96 hours in the f-box 
deficient, but not the wild-type cells, suggesting apoptosis had already 
commenced at these times. This confirmed GAK-mediated cell death by 
apoptosis preferentially in the FBXW7-/- HCT116 cells after 72 hours, 
compared to the wild-type cells. Interestingly, it was noticed that GAK levels 
are lower in the FBXW7-/- cells, although the reason for this is unclear. An 
Annexin V assay was undertaken to quantify the degree of apoptosis in the 
FBXW7 isogenic cells at 24-96 hours following siRNA transfection with GAK 
siGENOME SMARTpool compared to the NT control (Figure 4D). Similar 
results were obtained for the FBXW7 proficient and deficient cells with the 
control and GAK siRNA at 24 hours; mean viable cells were 93-97% versus 
apoptotic cells of 2-8%. From 48 hours onwards, the GAK RNAi consistently 
induced double the number of apoptotic cells in FBXW7-/- compared to the 
wild-type cells; 21% versus 8% at 48 hours and 29% versus 12% at 96 hours, 
respectively. Thus, confirming a preferential increase in apoptosis in the 
FBXW7-/- cell line in response to GAK RNAi compared to the wild-type 
controls from 48 hours incrementing to involve a fifth of cells by 72 hours 
(Figure 4D). 
 
Dual GAK-FBXW7 inhibition causes cell cycle disruption and perturbs 
mitosis. 
 
GAK RNAi has previously been reported to cause a mitotic arrest in HeLa 
cells (Shimizu et al, 2009), we assessed the global cell cycle effect of GAK 
RNAi on the FBXW7 isogenic cells, using flow cytometry. HCT116 cells were 
treated with mock, NT and GAK siGENOME SMARTpool siRNA, then the 
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DNA content analysed by PI staining 48-120 hours later (Figure 5A). At 48 
hours, the cell cycle profiles for both cell lines, under all conditions were 
similar, with a clear large 2n DNA peak (G1 cells) and smaller 4n DNA peak 
(G2/M). However, from 72 hours onwards, a clear difference became evident 
between the FBXW7 deficient and proficient cells when treated with the GAK 
siRNA. For the wild-type cells, at 72 hours there is a small decrease in the 2n 
population, however, in the FBXW7 null cells, this phenotype is much more 
dramatic, with the 2n peak being only as large as the 4n peak, with a 
concomitant increase in the sub-2n population (apoptotic cells). However, 
since the 4n peak remains the same size, this argues against a significant cell 
cycle arrest in G2 or mitosis. Furthermore, this phenotype gets progressively 
more intense over time, with a complete loss of the cell cycle by 120 hours, 
although the wild-type cells appear to be less severely affected by the GAK 
RNAi.  
 
Multipolar spindle formation in HeLa cells has also been reported following 
GAK RNAi (Shimizu et al, 2009). To ascertain if this holds true in HCT116 
cells and to determine if this phenotype is exacerbated in FBXW7-/- cells, 
immunofluorescence microscopy was performed at 48 and 72 hours following 
RNAi with NT and GAK SMARTpool RNAi in the HCT116 isogenic pair 
(Figure 5B-C). Cells were fixed and stained with antibodies against α-tubulin 
and Aurora A, to visualise the mitotic spindles and centrosomes (Figure 5B), 
respectively, and the number of multipolar cells quantified (Figure 5C). In both 
cells transfected with the NT control, the majority of mitotic cells contained 
bipolar spindles, with only a very small number of multi-polar mitoses being 
evident. However, following GAK RNAi, there was a clear induction in 
multipolar mitoses in both cell lines. The FBXW7-/- cells demonstrated a two-
fold increase in combined tri- and multipolar spindles compared to wild-type 
cells with 11% versus 2%, and 19% versus 11%, at 48 and 72 hours, 
respectively (Figure 5C). Importantly, not only was this phenotype more 
prominent in the FBXW7 null cells, but it was more severe, with up to 6 
spindle poles being identified in some cells, while generally only tri-polar 
formations were seen in the wild-type cells (Figure 5B). This suggests that the 
loss of GAK and FBXW7 may synergise in producing multipolar spindles. 
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GAK RNAi induced mitotic arrest has been documented in HeLa and U2OS 
cell lines (Shimizu et al, 2009). In addition to the cell cycle disruption identified 
predominantly in f-box deficient cells, we determined the effect of GAK 
silencing on mitotic duration, using time-lapse microscopy. FBXW7+/+ and -/- 
HCT116 cells were made to stably express histone H2B-mCherry, allowing 
the visualisation of the DNA. Time-lapse microscopy was performed 48 hours 
following transfection with NT or GAK SMARTpool siRNA (Figure 5D). Mitotic 
duration was calculated for 100 cells for each siRNA. Although small, we 
observed a statistically significant difference in the median mitotic duration for 
the NT controls between the FBXW7 proficient and deficient cells: 21 versus 
27 minutes, respectively (n = 100, p < 0.0001), perhaps suggesting a 
tendency for the FBXW7 null cells to have more problems aligning their 
chromosomes, as previously reported (Bailey et al, 2015; Rajagopalan et al, 
2004). For the cells treated with GAK RNAi, the median mitotic interval was 
increased to 30 min (95% CI 33.67 – 46.73) versus 33 min (43.03 – 57.59), 
respectively. Although this was not significantly different between the isogenic 
cells (n=100, p=0.23), it was constantly longer than the NT controls. This 
indicates that GAK does appear to play a role in the timing of mitosis in 
HCT116 cells; however it appears to be relatively minor and independent of 
FBXW7 function. Such a small increase may also explain why a difference 
was not apparent by flow cytometry. 
 
Synthetic lethal mechanism between FBXW7 and GAK is clathrin 
independent 
 
Pitstop 2, a cell permeable clathrin inhibitor (Dutta et al, 2012), and siRNA 
targeting the clathrin heavy chain (CHC) were utilized to evaluate if the 
synthetic lethal mechanism with FBXW7 was related to the clathrin function of 
GAK (Figure 6). In viability assays similar killing curves were apparent in the 
FBXW7 isogenic HCT116 cells following 5-day exposure to Pitstop 2 (Figure 
6A). Actually, the FBXW7-/- cells seemed to be slightly more insensitive to 
clathrin inhibition. Cell cycle profiling was undertaken at 24–48 hours following 
Pitstop 2 treatment at 40 and 80 μM (Figure 6B). A similar profile was seen for 
the controls at both concentrations and time points, with Pitstop 2 appearing 
to have no effect on the cell cycle profiles, with the exception of 80 μM at 48 
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hours in the wild-type cells. These cell cycle profiles are markedly different to 
the same cells lines in response to GAK RNAi (Figure 5A). This hypothesis 
was tested further using RNAi against clathrin (Figure 6C-E). Once again the 
FBXW7 deficient HCT116 cells were less sensitive to clathrin siRNA than the 
wild-type cells when using a proliferation assay, with statistically significantly 
different mean cell survival of 77% compared to 54% in the proficient 
comparators (Figure 6C); this correlates with the Pitstop 2 drug response. 
Secondly, there was no obvious alteration in the cell cycle profiles of either 
the FBXW7+/+ or -/- cells at 48-96 hours post clathrin siRNA transfection 
(Figure 6D) despite adequate clathrin knockdown (Figure 6E). All of these 
data together suggests that the toxicity associated with GAK knockdown is not 
mediated through clathrin binding in these FBXW7 isogenic cells. 
 
Discussion:  
A robust siRNA kinome screen identified GAK as a synthetic lethal target with 
FBXW7 loss. The use of SMARTpools maximised knockdown efficiency whilst 
minimising the individual siRNA dose. GAK validated strongly with 8 out of 8 
different siRNAs inducing statistically significant preferential death in HCT116 
FBXW7-/- with associated efficient gene silencing of the GAK protein. This 
markedly reduces the risk of these findings being due to off-target effects or 
activation of the interferon response (Kaelin, 2012; Sharma & Rao, 2009). 
 
GAK silencing, by two different SMARTpools, in breast basal FBXW7 deficient 
cells caused statistically significant increased cell death of 19% and 54% 
relative to the wild-type comparators. The FBXW7-GAK synthetic lethal 
relationship was not confirmed in the colorectal or gynaecological cell lines. 
This may be due to the fact that different molecular backgrounds 
(supplementary table 2) define sensitivity, such as is apparent clinically with 
the contrasting responses seen with single agent BRAF inhibitors in 
melanoma and colorectal cancers (Herr & Brummer, 2015). Wider exploration 
in larger cell line panels is not possible given the small numbers of FBXW7 
mutant cells available. 
  
We have demonstrated that GAK inhibition in FBXW7-/- HCT116 causes cell 
death that increases over time, detected by a variety of assays. From 48 
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hours the cell cycle is disrupted, followed by the induction of apoptosis at 72 
hours. By day 5, cell death was at 60-80%, which increased to 85-90% by day 
14. The prolonged nature of these effects suggests accumulation of cellular 
defects is necessary before death ensues.  
 
The work conducted focused on the role of GAK in mitotic spindle assembly 
and chromosomal alignment (Shimizu et al, 2009; Tanenbaum et al, 2010). 
Having demonstrated siRNA-mediated GAK silencing causes marked cell 
cycle disruption resulting in a raised sub-G1 alongside decreased G1 and 
G2/M cell cycle phases. Published work in HeLa cells has shown GAK RNAi 
induces mitotic arrest and increased G2/M peak (Shimizu et al, 2009). This 
discrepancy may simply reflect the different cell lines used. Also, the true 
phenotype of cellular GAK depletion has not reached a consensus, with 
conflicting data reported from different cell lines and groups (Lee et al, 2008). 
Contrary to GAK RNAi inducing mitotic arrest in HeLa cells (Shimizu et al, 
2009), there was only a minor mitotic delay of 3 minutes in both the FBXW7+/+ 
and -/- HCT116 cells, however, this was neither significant nor specific to loss 
of f-box functionality, suggesting that GAK is involved, but not essential for, 
mitotic progression concurring with previous reports (Shimizu et al, 2009). The 
differences between our and published data, may purely represent different 
cell line responses to GAK knockdown.  
 
The most marked phenotype of GAK RNAi induced multi-polar mitoses, which 
appeared to be augmented in the context of FBXW7 loss represents a notable 
outcome and mirrored data in the HeLa cell lines (Shimizu et al, 2009). Dual 
FBXW7-GAK inhibition increases multi-polar mitoses to approximately 20% at 
72 hours. This doubling, compared to the wild-type controls, could account for 
the increased cell death potentially through chromosomal mis-segregation 
resulting in aneuploidy (Duensing & Munger, 2001). This mechanism may 
account for the selective toxicity of GAK siRNA in FBXW7 deficient cells 
known to possess chromosomal instability, mainly documented by cyclin E 
over-expression (Loeb et al, 2005; Rajagopalan et al, 2004; Spruck et al, 
1999). The accumulation of mitotic defects through GAK inhibition could 
present a therapeutic strategy by inducing replicative stress, in a selective 
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manner, targeting the inherent mitotically unstable FBXW7-/- cells 
(Dobbelstein & Sorensen, 2015).  
 
We have identified a potential novel drug candidate for FBXW7 deficient 
tumours. The phenotype of mutual GAK-FBXW7 loss is unlikely to have 
resulted from clathrin or receptor-mediated endocytosis. The severe cell cycle 
disruption, with multi-polar defects mean it is more likely to be a mitotic defect 
although elucidating the exact mechanism of cell death has proven difficult. 
The GAK-FBXW7 deficient phenotype appears different to GAK inhibition in 
other cells (Shimizu et al, 2009; Tanenbaum et al, 2010) and not related to 
loss of the spindle assembly checkpoint in HCT116 cells (Bailey et al, 2015). 
Currently, there are no commercially available selective GAK inhibitors to 
allow the use of kinase inhibitors to simulate siRNA effects. Data have 
recently been published on the development of a GAK specific inhibitor 
although the potency is relatively low with the half maximal concentration 
(EC50) values in the 2-3 μM range (Kovackova et al, 2015); we were unable to 
access this for confirmation experiments at this juncture. Further studies are 
needed warranted including expansion of cell line work by blocking FBXW7 
activity in wild-type cells as well as to ascertaining if GAK inhibition is kinase 
dependent. 
 
A multitude of cancers would be good clinical candidates for specific GAK 
inhibitors including cholangiocarcinoma, since epithelial bile duct cancers are 
one of the highest mutated FBXW7 tumours, have poor prognosis and a 
paucity of therapeutic agents (Meza-Junco et al, 2010). Our data also support 
the potential use of GAK inhibitors in triple negative FBXW7 deficient tumours. 
During the development of any novel inhibitor, it is imperative to establish a 
robust predictive biomarker, which would be key to selecting preferential 
candidate compounds.  
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Figure legends:  
 
Figure 1: RNAi synthetic lethal screen. A. Schema of siRNA kinome screen. 
B.  Ranked mean ΔZ-scores, kinase hit threshold < -2 (n=2). C. Quantification 
of percentage survival of FBXW7+/+ (black) and -/- (grey) HCT116 cells 5 days 
post transfection with 8 individual GAK siRNAs from the deconvoluted 
siGENOME (1-4) and on-TARGET plus (5-8) SMART pools (n=3); mean + 
SEM. Paired T-test, * p<0.05, ** p<0.01, *** p<0.001. D. Immunoblot showing 
GAK and GAPDH levels in FBXW7+/+ and -/- cells 72 hours following GAK 
RNAi. 
  
Figure 2: Validation of FBXW7-GAK synthetic lethality in breast cells. A. 
Quantification of cell survival 5 days after transfection with GAK (G) 
siGENOME (SIG), left panel, and on-TARGET plus (OTP) siRNAs, right panel, 
relative to non targeting (N) and siTOX (T) controls (n=3). B. Median cell 
survival of the combined breast FBXW7 proficient versus deficient cells with N, 
T and G SIG and OTP siRNA. C. Immunoblot of GAK and GAPDH 72 hours 
post GAK SMARTpool RNAi. D. Combined analysis of breast cell survival by 
FBXW7 status using paired T-test, *** p<0.0001. 
 
Figure 3: FBXW7-GAK synthetic lethal relationship is not maintained in 
FBXW7 deficient gynaecological or colorectal cancer cell lines. A,D. 
Percentage cell survival 5 days post transfection with GAK siGENOME (G) 
siRNA compared to non-targeting (N) and siTOX (T) controls in 
gynaecological and colorectal cells, respectively (n=3). B,F. Combined 
analysis of gynaecological (B) and colorectal (F) cell survival by FBXW7 
status, N/S by paired T-test. C,E. Immunoblot of GAK and α–tubulin (α–tub) 
72 hours post GAK RNAi in gynaecological (C) and colorectal (F) cells.  
 
Figure 4: Dual GAK-FBXW7 inhibition induces apoptosis in HCT116 
FBXW7 deficient cells. A-B.  Long-term proliferation assay of FBXW7+/+ and 
-/- HCT116 cells 14 days following RNAi with GAK siGENOME (SiG) and on-
TARGET plus (OTP) compared to non-targeting (NT) siRNA. A. Images of 
fixed and stained cells. B. Quantification of Sulforhodamine B assay by paired 
T-test, ****p<0.0001. C.  Immunoblot of GAK, cleaved PARP (cPARP) and 
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GAPDH 72 and 96 hours post GAK and NT RNAi. D. Annexin V assay of 
FBXW7+/+ and -/- HCT116 cells at 24-96 hours following GAK siGENOME 
SMARTpool (G) and non-targeting (N) siRNA. Cells are deemed apoptotic if 
they stain for propidium iodide (PI) and/or Annexin V (AnV) or viable if they 
are PI- and AnV positive (+) or negative (-). 
 
Figure 5: GAK silencing in FBXW7 deficient cells perturbs mitosis. A. 
DNA content of asynchronous FBXW7+/+ and -/- HCT116 cells at indicated 
time-points following transfection with mock, non-targeting (NT) and GAK 
siRNA. Propidium iodide (PI) staining was analysed by flow cytometry.  B. 
Immunofluorescence of PEM fixed FBXW7+/+ and -/- HCT116 cells stained with 
DAPI (blue), α-tubulin (green), Aurora A (red) 72 hours following transfection 
with NT and GAK siRNA. C. Quantification of multi-polar mitoses identified by 
immunofluorescence at 48 and 72 hours post GAK siGENOME RNAi. D. 
Mitotic duration at 48 hours following GAK and NT siRNA, measured from 
time of nuclear envelope breakdown (NEBD) to anaphase onset in FBXW7+/+ 
(black) and -/- (grey) HCT116 cells stably expressing histone-H2B-mCherry, 
n=100. Paired student T-tests, **** p <0.0001. 
 
Figure 6: Clathrin inhibition through RNAi and Pitstop 2 does not 
mirror phenotype observed with GAK inhibition in isogenic HCT116 
cells. A. Pitstop 2 growth inhibition curves of % survival fraction of FBXW7+/+ 
(black) and -/- (grey) HCT116 at day 5. Growth inhibitory concentrations (GI50) 
were 30.51 μM (95% CI 25.9-35) and 43.81 μM (95% CI 41.7-45.9), 
respectively; not significant by T-Test (p=0.3).  B. DNA content of 
asynchronous FBXW7+/+ and -/- HCT116 cells at 24 and 48 hours post 
treatment with Pitstop 2 at the indicated concentrations. C. Quantification of 
cell survival following mock, non targeting (NT) and clathrin heavy chain 
(CHC) RNAi, compared by paired T-tests, **** p<0.0001. D. Propidium iodide 
staining (DNA content) for asynchronous cells 48-96 hours following 
transfection with mock, NT and CHC siRNA. E. Immunoblot of CHC and 
GAPDH for HCT116 FBXW7+/+ and -/- cells 72 hours post RNAi.  
 
Supplementary Figure 1: Kinome siRNA screen metrics. A. Correlation 
curves of Z-scores of the biological duplicates performed for individual wells 
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for each cell line. The linear regression coefficient (R2) for run 1 versus run 2 
FBXW7+/+ and -/- HCT116 cells was 0.89 and 0.85, respectively. B. Mean Z’ 
factor for the isogenic cells biological duplicate replicates. C. Scatter plots of 
mean ΔZ-scores for the non-targeting (NT) and siTOX siRNA controls. 
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Supplementary Table 1: Top hits from the secondary screen using the 
siGENOME deconvoluted siRNA 
 
siRNA Full Name % Cell viability HCT116 p value 
  FBXW7+/+ FBXW7-/-  
NT 
Non targeting 
control 100.0 100.0 0.50 
siTOX siTOX control 2.0 2.2 0.40 
GAK Cyclin G associated 
kinase 
69.8 47.7 0.02 
GAK 50.8 12.1 0.00 
GAK 54.0 11.8 0.00 
GAK 32.3 7.8 0.02 
BUB1B Budding uninhibited 
by benzimidazoles 1 
50.6 36.5 0.04 
BUB1B 63.1 35.4 0.01 
BUB1B 50.3 25.4 0.01 
BUB1B 19.3 17.2 0.31 
FGFR1 Fibroblast growth 
factor receptor 1 
49.2 25.1 0.05 
FGFR1 64.5 45.5 0.03 
FGFR1 63.9 48.5 0.07 
FGFR1 78.1 71.5 0.12 
BCKDK Branched chain 
ketoacid 
dehydrogenase 
3.1 2.4 0.00 
BCKDK 92.0 78.9 0.02 
BCKDK 107.6 94.1 0.10 
BCKDK 40.9 40.7 0.47 
RET RET proto-
oncogene 
78.3 60.6 0.01 
RET 24.9 6.9 0.00 
RET 14.4 12.9 0.12 
RET 86.1 86.3 0.46 
FN3KRP Fructosamine 3 
kinase related 
protein 
66.7 50.8 0.02 
FN3KRP 34.1 21.7 0.05 
FN3KRP 34.2 41.5 0.11 
FN3KRP 30.9 40.9 0.00 
TRIB2 Tribbles homolog 2 7.6 4.6 0.00 
TRIB2 24.8 13.9 0.01 
TRIB2 101.7 100.4 0.41 
TRIB2 102.1 104.7 0.26 
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Supplementary Table 2:  Overview of breast, gynaecological and colon 
cancer cell lines used to validate FBXW7-GAK synthetic lethal 
partnership 
 
Cell line Tumour type 
 
FBXW7 
alteration 
FBXW7 phenotype 
 
Other mutations 
PI
K3
C
A
 
P5
3 
PT
EN
 
R
A
S/
R
AF
 
N
ot
ab
le
 
O
th
er
s 
BREAST 
SUM149PT Breast: basal B IDC ER- 
PR- 
F549fs*6 Homozygous nonsense 
mutation causing truncation 
of WD40 
     
HCC1143 Breast: basal A IDC ER- 
PR- 
Wildtype Mono-allelic deletion of 
FBXW7 gene 
     
T47D Breast: luminal A IDC 
ER+ PR+ 
Wildtype  + +    
MCF7 Breast: luminal A IDC 
ER+ PR+ 
Wildtype  +     
GYNAECOLOGICAL 
AN3-CA Endometrial: 
adenocarcinoma 
R441W Heterozygous missense 
WD40 
 +   MET 
SK-O-V3 Ovarian: 
adenocarcinoma 
R505L Heterozygous missense 
WD40 of conserved arginine 
+    NF1 
HEC1B Endometrial: 
adenocarcinoma 
R367* Nonsense upstream of 
WD40 
   + 
KRAS 
HRAS 
 
ES-2 Ovarian: clear cell 
carcinoma 
Wildtype     + 
BRAF 
 
MFE-296 Endometrial: 
adenocarcinoma 
Wildtype  + + +   
ISHIKAWA Endometrial: 
adenocarcinoma 
Wildtype   + +   
EFE184 Endometrial:  
carcinoma 
Wildtype 
 
      
OVISE Ovarian: 
adenocarcinoma 
Wildtype       
SNG-M Endometrial: 
adenocarcinoma 
Wildtype  +  +   
HEC1A Endometrial: 
adenocarcinoma 
Wildtype  +    NF1 
COLON 
LoVo Colon:  
adenocarcinoma 
R505L Heterozygous missense 
WD40 of conserved arginine 
   + NF1 
SNU407 Colon:  
adenocarcinoma 
R465C Heterozygous missense 
WD40 of conserved arginine 
+  + + 
BRAF 
 
SW837 Rectal:  
adenocarcinoma 
L403fs*34 Heterozygous Frameshift in 
WD40 
   + 
KRAS 
 
SW48 Colon:  
adenocarcinoma 
S668fs*39 Heterozygous Frameshift in 
WD40 
+  + + 
HRAS 
MS
H6 
HT55 Colon:  
adenocarcinoma 
T8S Homozygous missense    + 
BRAF 
NF1 
HT-29 Colon:  
carcinoma 
Wildtype  +   + 
BRAF 
 
COLO-741 Colon:  
carcinoma 
Wildtype      MLH
1 
MAWI Colon:  
carcinoma 
Wildtype     + 
BRAF 
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